Europe Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), andOthers),Product Type (Software and Device), and Sales Channel (Business-to-Business(B2B) and Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2019–2026
The Europe digital therapeutics market was valued at $503.48 million in 2018 and is expected to reach $2,274.03 million by 2026 with a CAGR of 20.6% during the forecast period.
Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding the design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidence of chronic diseases drive the growth of the Europe digital therapeutics market. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.6% from 2019 to 2026. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future.
The Europe digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product type, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employers, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers. Region wise, it is analyzed across UK, Germany, France, Italy, Spain, Russia, and Rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding the design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidence of chronic diseases drive the growth of the Europe digital therapeutics market. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.6% from 2019 to 2026. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future.
The Europe digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product type, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employers, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers. Region wise, it is analyzed across UK, Germany, France, Italy, Spain, Russia, and Rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2026, which assists to identify the prevailing market opportunities.
- An in-depth analysis of Europe regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate this region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the Europe digital therapeutics market is provided.
- By Application
- Diabetes
- Obesity
- Cardiovascular Disease (CVD)
- Central Nervous System (CNS) Disease
- Respiratory Disease
- Smoking Cessation
- Gastrointestinal Disorder (GID)
- Others
- By Product Type
- Software
- Device
- By Product Type
- Business-to-Business (B2B)
- Employer
- Healthcare Provider
- Others
- Business-to-Consumer (B2C)
- Patient
- Caregiver
- By Country
- UK
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Fitbit, Inc. (Twine Health, Inc.)
- Medtronic Plc.
- Novartis International AG (Pear Therapeutics, Inc.)
- Resmed, Inc. (Propeller Health)
- Voluntis, Inc.
- Ada Health GmbH
- Cognifit ltd
- Caterna Vision GmbH
- Sonormed GmbH
- Kaia Health
- GlaxoSmithKline
- Veeva Systems
- Syneos Health
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Top player positioning, 2018
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in adoption of smartphones and tablets coupled with healthcare apps
3.4.1.2.Growth in need to control healthcare costs
3.4.1.3.Rise in incidences of chronic diseases
3.4.2.Restraints
3.4.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.4.2.2.Patient data privacy concerns
3.4.3.Opportunity
3.4.3.1.Emerging markets offer significant growth opportunities
CHAPTER 4:EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market analysis, by country
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market analysis, by country
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market analysis, by country
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market analysis, by country
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market analysis, by country
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market analysis, by country
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market analysis, by country
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market analysis, by country
CHAPTER 5:EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market analysis, by country
5.3.Devices
5.3.1.Market analysis, by country
CHAPTER 6:EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-to-business (B2B)
6.2.1.Market size and forecast, by type
6.2.1.1.Employer
6.2.1.1.1.Market size and forecast
6.2.1.2.Healthcare Providers
6.2.1.2.1.Market size and forecast
6.2.1.3.Others
6.2.1.3.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Business-to-consumers (B2C)
6.3.1.Market size and forecast, by type
6.3.1.1.Patients
6.3.1.1.1.Market size and forecast
6.3.1.2.Caregivers
6.3.1.2.1.Market size and forecast
6.3.2.Market analysis, by country
CHAPTER 7:EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY
7.1.Overview
7.2.Key market trends, growth factors, and opportunities
7.3.Europe digital therapeutics market, by country
7.3.1.UK digital therapeutics market, by application
7.3.2.UK digital therapeutics market, by product type
7.3.3.UK digital therapeutics market, by sales channel
7.3.4.Germany digital therapeutics market, by application
7.3.5.Germany digital therapeutics market, by product type
7.3.6.Germany digital therapeutics market, by sales channel
7.3.7.France digital therapeutics market, by application
7.3.8.France digital therapeutics market, by product type
7.3.9.France digital therapeutics market, by sales channel
7.3.10.Italy digital therapeutics market, by application
7.3.11.Italy digital therapeutics market, by product type
7.3.12.Italy digital therapeutics market, by sales channel
7.3.13.Spain digital therapeutics market, by application
7.3.14.Spain digital therapeutics market, by product type
7.3.15.Spain digital therapeutics market, by sales channel
7.3.16.Russia digital therapeutics market, by application
7.3.17.Russia digital therapeutics market, by product type
7.3.18.Russia digital therapeutics market, by sales channel
7.3.19.Rest of Europe digital therapeutics market, by application
7.3.20.Rest of Europe digital therapeutics market, by product type
7.3.21.Rest of Europe digital therapeutics market, by sales channel
7.4.Europe digital therapeutics market, by application
7.5.Europe digital therapeutics market, by product type
7.6.Europe digital therapeutics market, by sales channel
CHAPTER 8:COMPANY PROFILES
8.1.ADA HEALTH GMBH
8.1.1.Company overview
8.1.2.Product portfolio
8.1.3.Key strategic moves and developments
8.2.COGNIFIT
8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments
8.3.CATERNA VISION GMBH
8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio
8.4.FITBIT, INC. (TWINE HEALTH, INC.)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.5.KAIA HEALTH
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.6.MEDTRONIC PLC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.RESMED, INC. (PROPELLER HEALTH)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SONORMED GMBH
8.9.1.Company overview
8.9.2.Product portfolio
8.10.VOLUNTIS, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Top player positioning, 2018
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in adoption of smartphones and tablets coupled with healthcare apps
3.4.1.2.Growth in need to control healthcare costs
3.4.1.3.Rise in incidences of chronic diseases
3.4.2.Restraints
3.4.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.4.2.2.Patient data privacy concerns
3.4.3.Opportunity
3.4.3.1.Emerging markets offer significant growth opportunities
CHAPTER 4:EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market analysis, by country
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market analysis, by country
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market analysis, by country
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market analysis, by country
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market analysis, by country
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market analysis, by country
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market analysis, by country
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market analysis, by country
CHAPTER 5:EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market analysis, by country
5.3.Devices
5.3.1.Market analysis, by country
CHAPTER 6:EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-to-business (B2B)
6.2.1.Market size and forecast, by type
6.2.1.1.Employer
6.2.1.1.1.Market size and forecast
6.2.1.2.Healthcare Providers
6.2.1.2.1.Market size and forecast
6.2.1.3.Others
6.2.1.3.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Business-to-consumers (B2C)
6.3.1.Market size and forecast, by type
6.3.1.1.Patients
6.3.1.1.1.Market size and forecast
6.3.1.2.Caregivers
6.3.1.2.1.Market size and forecast
6.3.2.Market analysis, by country
CHAPTER 7:EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY
7.1.Overview
7.2.Key market trends, growth factors, and opportunities
7.3.Europe digital therapeutics market, by country
7.3.1.UK digital therapeutics market, by application
7.3.2.UK digital therapeutics market, by product type
7.3.3.UK digital therapeutics market, by sales channel
7.3.4.Germany digital therapeutics market, by application
7.3.5.Germany digital therapeutics market, by product type
7.3.6.Germany digital therapeutics market, by sales channel
7.3.7.France digital therapeutics market, by application
7.3.8.France digital therapeutics market, by product type
7.3.9.France digital therapeutics market, by sales channel
7.3.10.Italy digital therapeutics market, by application
7.3.11.Italy digital therapeutics market, by product type
7.3.12.Italy digital therapeutics market, by sales channel
7.3.13.Spain digital therapeutics market, by application
7.3.14.Spain digital therapeutics market, by product type
7.3.15.Spain digital therapeutics market, by sales channel
7.3.16.Russia digital therapeutics market, by application
7.3.17.Russia digital therapeutics market, by product type
7.3.18.Russia digital therapeutics market, by sales channel
7.3.19.Rest of Europe digital therapeutics market, by application
7.3.20.Rest of Europe digital therapeutics market, by product type
7.3.21.Rest of Europe digital therapeutics market, by sales channel
7.4.Europe digital therapeutics market, by application
7.5.Europe digital therapeutics market, by product type
7.6.Europe digital therapeutics market, by sales channel
CHAPTER 8:COMPANY PROFILES
8.1.ADA HEALTH GMBH
8.1.1.Company overview
8.1.2.Product portfolio
8.1.3.Key strategic moves and developments
8.2.COGNIFIT
8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments
8.3.CATERNA VISION GMBH
8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio
8.4.FITBIT, INC. (TWINE HEALTH, INC.)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.5.KAIA HEALTH
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.6.MEDTRONIC PLC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.RESMED, INC. (PROPELLER HEALTH)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SONORMED GMBH
8.9.1.Company overview
8.9.2.Product portfolio
8.10.VOLUNTIS, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.EUROPE DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 03.EUROPE DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 04.EUROPE DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 05.EUROPE DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 06.EUROPE DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 07.EUROPE DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 08.EUROPE DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 09.EUROPE DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 11.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 12.EUROPE DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 13.EUROPE DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 15.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO- CONSUMERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 19.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 21.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 22.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 23.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 25.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 26.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 27.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 28.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 29.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 30.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 31.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 32.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 33.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 34.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 35.RUSSIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36.RUSSIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 37.RUSSIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 38.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 39.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 40.REST OF DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 41.DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42.DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 43.DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 44.ADA: COMPANY SNAPSHOT
TABLE 45.ADA: PRODUCT PORTFOLIO
TABLE 46.COGNIFIT: COMPANY SNAPSHOT
TABLE 47.COGNIFIT: OPERATING SEGMENT:
TABLE 48.COGNIFIT: PRODUCT PORTFOLIO
TABLE 49.CATERNA: COMPANY SNAPSHOT
TABLE 50.CATERNA: PRODUCT PORTFOLIO
TABLE 51.FITBIT: COMPANY SNAPSHOT
TABLE 52.FITBIT: PRODUCT PORTFOLIO
TABLE 53.KAIA HEALTH: COMPANY SNAPSHOT
TABLE 54.KAIA: OPERATING SEGMENT:
TABLE 55.KAIA: PRODUCT PORTFOLIO
TABLE 56.MEDTRONIC: COMPANY SNAPSHOT
TABLE 57.MEDTRONIC: OPERATING SEGMENTS
TABLE 58.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 59.NOVARTIS: COMPANY SNAPSHOT
TABLE 60.NOVARTIS: OPERATING SEGMENTS
TABLE 61.NOVARTIS: PRODUCT PORTFOLIO
TABLE 62.RESMED: COMPANY SNAPSHOT
TABLE 63.RESMED: OPERATING SEGMENTS
TABLE 64.RESMED: PRODUCT PORTFOLIO
TABLE 65.SONORMED: COMPANY SNAPSHOT
TABLE 66.SONORMED: PRODUCT PORTFOLIO
TABLE 67.VOLUNTIS: COMPANY SNAPSHOT
TABLE 68.VOLUNTIS: OPERATING SEGMENTS
TABLE 69.VOLUNTIS: PRODUCT PORTFOLIO
TABLE 01.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.EUROPE DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 03.EUROPE DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 04.EUROPE DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 05.EUROPE DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 06.EUROPE DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 07.EUROPE DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 08.EUROPE DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 09.EUROPE DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 11.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 12.EUROPE DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 13.EUROPE DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 15.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO- CONSUMERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 19.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 21.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 22.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 23.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 25.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 26.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 27.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 28.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 29.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 30.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 31.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 32.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 33.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 34.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 35.RUSSIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36.RUSSIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 37.RUSSIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 38.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 39.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 40.REST OF DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 41.DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42.DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 43.DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 44.ADA: COMPANY SNAPSHOT
TABLE 45.ADA: PRODUCT PORTFOLIO
TABLE 46.COGNIFIT: COMPANY SNAPSHOT
TABLE 47.COGNIFIT: OPERATING SEGMENT:
TABLE 48.COGNIFIT: PRODUCT PORTFOLIO
TABLE 49.CATERNA: COMPANY SNAPSHOT
TABLE 50.CATERNA: PRODUCT PORTFOLIO
TABLE 51.FITBIT: COMPANY SNAPSHOT
TABLE 52.FITBIT: PRODUCT PORTFOLIO
TABLE 53.KAIA HEALTH: COMPANY SNAPSHOT
TABLE 54.KAIA: OPERATING SEGMENT:
TABLE 55.KAIA: PRODUCT PORTFOLIO
TABLE 56.MEDTRONIC: COMPANY SNAPSHOT
TABLE 57.MEDTRONIC: OPERATING SEGMENTS
TABLE 58.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 59.NOVARTIS: COMPANY SNAPSHOT
TABLE 60.NOVARTIS: OPERATING SEGMENTS
TABLE 61.NOVARTIS: PRODUCT PORTFOLIO
TABLE 62.RESMED: COMPANY SNAPSHOT
TABLE 63.RESMED: OPERATING SEGMENTS
TABLE 64.RESMED: PRODUCT PORTFOLIO
TABLE 65.SONORMED: COMPANY SNAPSHOT
TABLE 66.SONORMED: PRODUCT PORTFOLIO
TABLE 67.VOLUNTIS: COMPANY SNAPSHOT
TABLE 68.VOLUNTIS: OPERATING SEGMENTS
TABLE 69.VOLUNTIS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN DIGITAL THERAPEUTICSS MARKET, 2018
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019*
FIGURE 06.TOP PLAYER POSITIONING, 2018
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.EUROPE DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13.EUROPE DIGITAL THERAPEUTICS MARKET BY APPLICATION
FIGURE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 15.EUROPE DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER, 2018–2026 ($MILLION)
FIGURE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2018–2026 ($MILLION)
FIGURE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS, 2018–2026 ($MILLION)
FIGURE 19.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2018–2026 ($MILLION)
FIGURE 20.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2018–2026 ($MILLION)
FIGURE 21.FITBIT: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.FITBIT: NET SALES BY REGION, 2018 (%)
FIGURE 23.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 25.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 26.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.RESMED: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.RESMED: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.RESMED: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.VOLUNTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.VOLUNTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.VOLUNTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN DIGITAL THERAPEUTICSS MARKET, 2018
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019*
FIGURE 06.TOP PLAYER POSITIONING, 2018
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.EUROPE DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13.EUROPE DIGITAL THERAPEUTICS MARKET BY APPLICATION
FIGURE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 15.EUROPE DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER, 2018–2026 ($MILLION)
FIGURE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2018–2026 ($MILLION)
FIGURE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS, 2018–2026 ($MILLION)
FIGURE 19.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2018–2026 ($MILLION)
FIGURE 20.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2018–2026 ($MILLION)
FIGURE 21.FITBIT: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.FITBIT: NET SALES BY REGION, 2018 (%)
FIGURE 23.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 25.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 26.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.RESMED: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.RESMED: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.RESMED: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.VOLUNTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.VOLUNTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.VOLUNTIS: REVENUE SHARE BY REGION, 2018 (%)
